Neonatal Medicine

The Korean Society of Neonatology (대한신생아학회)
권호 표지
DOI QR코드

DOI QR Code

Factors Associated with Clinical Response to Low-Dose Dexamethasone Therapy for Bronchopulmonary Dysplasia in Very Low Birth Weight Infants

  • Shin, Jeongmin (Department of Pediatrics, Seoul National University Bundang Hospital) ;
  • Kim, Seh Hyun (Department of Pediatrics, Seoul National University Bundang Hospital) ;
  • Jung, Young Hwa (Department of Pediatrics, Seoul National University Bundang Hospital) ;
  • Choi, Chang Won (Department of Pediatrics, Seoul National University Bundang Hospital) ;
  • Kim, Beyong Il (Department of Pediatrics, Seoul National University Bundang Hospital)
  • Received : 2020.03.25
  • Accepted : 2020.05.04
  • Published : 2020.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To identify factors associated with the clinical response to low-dose dexamethasone therapy (LDDT) in preterm infants for bronchopulmonary dysplasia (BPD). Methods: We used a retrospective medical record review to evaluate preterm infants who were born before 32 weeks of gestation or with a birth weight less than 1,500 g. All infants were admitted to the neonatal intensive care unit at a tertiary academic hospital between January 2010 and June 2019, and received LDDT for BPD. The preterm infants' respiratory severity scores (RSS) were calculated from the first day of LDDT to the day of extubation, or the last day of LDDT. A good response was defined as a decreasing RSS with a slope greater than 0.181. A poor response was defined as a non-decreasing RSS, or a decreasing RSS with a slope less than 0.181 during LDDT. A total dose of 1.1 mg/kg was administered for 10 days for each single course of LDDT. Results: A total of 51 preterm infants were included in the final analysis. Thirty preterm infants (58.8 %) were in the good response group, and 21 preterm infants (41.2%) were in the poor response group. There were no significant differences in gestational age, birth weight, and sex between the good response group and poor response group. Preterm premature rupture of membrane and histologic chorioamnionitis were significantly associated with a poor response to LDDT. Higher RSS on the first day of the LDDT was associated with a good response to LDDT. Conclusion: Antenatal infection and/or inflammation may be associated with an unfavorable response to postnatal LDDT for BPD. Preterm infants with more severe respiratory failure seem to benefit more from LDDT for BPD.

Keywords

References

  1. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007;357:1946-55. https://doi.org/10.1056/NEJMra067279
  2. Jo HS, Cho KH, Cho SI, Song ES, Kim BI. Recent changes in the incidence of bronchopulmonary dysplasia among very-low-birth-weight infants in Korea. J Korean Med Sci 2015;30 Suppl 1:S81-7. https://doi.org/10.3346/jkms.2015.30.S1.S81
  3. Kim JK, Chang YS, Sung S, Ahn SY, Yoo HS, Park WS. Trends in survival and incidence of bronchopulmonary dysplasia in extremely preterm infants at 23-26 weeks gestation. J Korean Med Sci 2016;31:423-9. https://doi.org/10.3346/jkms.2016.31.3.423
  4. Manktelow BN, Draper ES, Annamalai S, Field D. Factors affecting the incidence of chronic lung disease of prematurity in 1987, 1992, and 1997. Arch Dis Child Fetal Neonatal Ed 2001;85:F33-5. https://doi.org/10.1136/fn.85.1.F33
  5. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015;314:1039-51. https://doi.org/10.1001/jama.2015.10244
  6. Doyle LW, Ehrenkranz RA, Halliday HL. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2014;5:CD001146.
  7. Lin YJ, Yeh TF, Hsieh WS, Chi YC, Lin HC, Lin CH. Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. Pediatr Pulmonol 1999;27:21-6.
  8. Olaloko O, Mohammed R, Ojha U. Evaluating the use of corticosteroids in preventing and treating bronchopulmonary dysplasia in preterm neonates. Int J Gen Med 2018;11:265-74. https://doi.org/10.2147/IJGM.S158184
  9. Groneck P, Reuss D, Gotze-Speer B, Speer CP. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. J Pediatr 1993;122:938-44. https://doi.org/10.1016/s0022-3476(09)90024-5
  10. Gupta S, Prasanth K, Chen CM, Yeh TF. Postnatal corticosteroids for prevention and treatment of chronic lung disease in the preterm newborn. Int J Pediatr 2012;2012:315642.
  11. Ehrenkranz RA, Mercurio MR. Bronchopulmonary dysplasia. In: Sinclair JC, Bracken MB, translators. Effective care of the newborn infant. Oxford: Oxford University Press, 1992:399-424.
  12. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2017;10:CD002058.
  13. Onland W, De Jaegere AP, Offringa M, van Kaam A. Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017;1:CD010941.
  14. Michael Z, Spyropoulos F, Ghanta S, Christou H. Bronchopulmonary dysplasia: an update of current pharmacologic therapies and new approaches. Clin Med Insights Pediatr 2018;12:1179556518817322.
  15. Onland W, Cools F, Kroon A, Rademaker K, Merkus MP, Dijk PH, et al. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial. JAMA 2019;321:354-63. https://doi.org/10.1001/jama.2018.21443
  16. Morris IP, Goel N, Chakraborty M. Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis. Eur J Pediatr 2019;178:1171-84. https://doi.org/10.1007/s00431-019-03398-5
  17. Kalikkot Thekkeveedu R, Guaman MC, Shivanna B. Bronchopulmonary dysplasia: a review of pathogenesis and pathophysiology. Respir Med 2017;132:170-7. https://doi.org/10.1016/j.rmed.2017.10.014
  18. Gien J, Kinsella JP. Pathogenesis and treatment of bronchopulmonary dysplasia. Curr Opin Pediatr 2011;23:305-13. https://doi.org/10.1097/MOP.0b013e328346577f
  19. Salafia CM, Weigl C, Silberman L. The prevalence and distribution of acute placental inflammation in uncomplicated term pregnancies. Obstet Gynecol 1989;73:383-9.
  20. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 2013;13:59. https://doi.org/10.1186/1471-2431-13-59
  21. Bhandari V. Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol 2014;100:189-201. https://doi.org/10.1002/bdra.23220
  22. Thebaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers 2019;5:78. https://doi.org/10.1038/s41572-019-0127-7
  23. Avery ME, Tooley WH, Keller JB, Hurd SS, Bryan MH, Cotton RB, et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 1987;79:26-30.
  24. Trembath A, Laughon MM. Predictors of bronchopulmonary dysplasia. Clin Perinatol 2012;39:585-601. https://doi.org/10.1016/j.clp.2012.06.014
  25. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB; DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006;117:75-83. https://doi.org/10.1542/peds.2004-2843
  26. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (>7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017;10:CD001145.
  27. Torchin H, Ancel PY, Goffinet F, Hascoet JM, Truffert P, Tran D, et al. Placental complications and bronchopulmonary dysplasia: EPIPAGE-2 cohort study. Pediatrics 2016;137:e20152163. https://doi.org/10.1542/peds.2015-2163
  28. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;164:1971-80. https://doi.org/10.1164/ajrccm.164.10.2101140
  29. Speer CP. Pulmonary inflammation and bronchopulmonary dysplasia. J Perinatol 2006;26 Suppl 1:S57-62. https://doi.org/10.1038/sj.jp.7211476
  30. Choi CW. Chorioamnionitis: is a major player in the development of bronchopulmonary dysplasia? Korean J Pediatr 2017;60:203-7. https://doi.org/10.3345/kjp.2017.60.7.203
  31. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001;1:1. https://doi.org/10.1186/1471-2431-1-1
  32. Halliday HL, Ehrenkranz RA. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001;2:CD001145.
  33. Doyle LW, Cheong JLY. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia: who might benefit? Semin Fetal Neonatal Med 2017;22:290-5. https://doi.org/10.1016/j.siny.2017.07.003
  34. Cheong JL, Burnett AC, Lee KJ, Roberts G, Thompson DK, Wood SJ, et al. Association between postnatal dexamethasone for treatment of bronchopulmonary dysplasia and brain volumes at adolescence in infants born very preterm. J Pediatr 2014;164:737-43. https://doi.org/10.1016/j.jpeds.2013.10.083
  35. Jobe AH. Postnatal corticosteroids for bronchopulmonary dysplasia. Clin Perinatol 2009;36:177-88. https://doi.org/10.1016/j.clp.2008.09.016
  36. Zeng L, Tian J, Song F, Li W, Jiang L, Gui G, et al. Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis. Arch Dis Child Fetal Neonatal Ed 2018;103:F506-11. https://doi.org/10.1136/archdischild-2017-313759
  37. Cuna A, Lewis T, Dai H, Nyp M, Truog WE. Timing of postnatal corticosteroid treatment for bronchopulmonary dysplasia and its effect on outcomes. Pediatr Pulmonol 2019;54:165-70.